Li Low-Jia, Chong Qingyun, Wang Lingzhi, Cher Goh Boon, Soo Ross A
Department of Haematology-Oncology, National University Hospital, Singapore, Singapore.
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
J Thorac Dis. 2020 Jul;12(7):3785-3795. doi: 10.21037/jtd.2019.08.63.
Differences in efficacy and toxicity between Asian and Caucasian patients with lung cancer treated with systemic chemotherapy is increasingly recognised. This is a major concern in the clinical setting as it influences outcomes and affect international harmonization of drug development. Interindividual variability of pharmacokinetics, where different genetic polymorphisms affect drug metabolism, transport, and receptor binding may account for the ethnic differences. Treatment efficacy and outcomes may also be explained by differences in diet and lifestyle, access to healthcare, cultural barriers and environmental exposure. Efforts made to design prospective studies investigating ethnic specific determinants to systemic therapy and individualise lung cancer treatment based on genetic makeup of patient are important.
越来越多的人认识到，接受全身化疗的亚洲和白种肺癌患者在疗效和毒性方面存在差异。在临床环境中，这是一个主要问题，因为它会影响治疗结果，并影响药物研发的国际协调。药代动力学的个体间差异，即不同的基因多态性影响药物代谢、转运和受体结合，可能是种族差异的原因。饮食和生活方式、医疗保健的可及性、文化障碍和环境暴露的差异也可能解释治疗效果和结果。开展前瞻性研究，调查全身治疗的种族特异性决定因素，并根据患者的基因构成实现肺癌治疗个体化，这些努力很重要。
